MaaT Pharma   Report issue

For profit Phase 2 Phase 3
Founded: Lyon France (2014)

Organization Overview

First Clinical Trial
2016
NCT02928523
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

MaaT Pharma

Active Ingredients

Drugs in Phase 3 Trials (1)

maat013 (2 trials)

Drugs in Phase 2 Trials (3)

autologous fecal microbiota (1 trial)

human fecal microbiota (Reybota) (2 trials)

maat033 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dysbiosis (Phase 2)

Hematologic Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4